Welcome to our annual celebration of the great and inspirational minds that contribute to the development and manufacture of new medicinal products
The Power List 2022 focuses on the top 10 VIPs in three key categories of medicine making
Medicare publishes policy for amyloid mAbs and Alzheimer’s disease. It’s not good news for Aduhelm.
How an initiative from EFPIA and a new public database on chemical substances could reduce animal experiments.
We find out how technology is enabling remote inspections in the pharma industry.
With the FDA still behind on inspections, manufacturers need to uncover their own blindspots.
Reconfigure. Redefine. Why modular cleanroom furniture is essential for a changing pharmaceutical market.
That which we call rosaimab by any other name would find regulatory approval and commercial success. Or would it?
What is going on with Aduhelm? And why is the drug seen by some to be controversial?
An industry consortium is tackling one of pharma’s biggest drug-related challenges.
IFPMA’s Director-General, Thomas Cueni, outlines how companies worldwide can foster long-term tech transfer partnerships.
It’s time for pharma companies to embrace digital technologies.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.
The Human Cost of Poor Practice
Getting Started With Digitization
Positive Opinion for Regeneron’s Libtayo